In 2022, Bristol Myers Squibb developed a fixed-dose combination immunotherapy (Nivolumab and relatlimab-rmbw; OpdualagTM) for the treatment of multiple types of advanced cancer, which is the first FDA-approved LAG3 monoclonal antibody combination therapy, making LAG3 the third immune checkpoint in clinical use after PD-1 and CTLA-4. The gene discussed is LAG3; the disease is cancer.